Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

Area of Science:

• Oncology
• Immunology
• Transplantation

Background:

• Immune checkpoint inhibitors, particularly programmed cell death 1 (PD-1) inhibitors, represent significant advancements in cancer therapy, approved for various advanced cancers.
• The use of PD-1 inhibitors in renal transplant recipients with advanced cancer is limited due to the risk of T-cell-mediated graft rejection, as T-cells target both tumor antigens and donor alloantigens.
• There is a critical need for optimal treatment regimens that enhance tumor-specific T-cell responses while minimizing alloreactivity in kidney transplant patients undergoing PD-1 inhibitor therapy.

Purpose of the Study:

• To review existing literature on kidney-transplanted patients treated with PD-1 inhibitors for advanced malignancy.
• To identify feasible approaches and suggest potential treatment strategies for managing advanced cancer in renal transplant recipients receiving PD-1 inhibitors.
• To explore the safety and efficacy of PD-1 inhibitors in this specific patient population.

Main Methods:

• Systematic review of published case reports and clinical data concerning kidney-transplanted patients treated with PD-1 inhibitors.
• Analysis of treatment regimens, including immunosuppressive strategies, and their impact on graft survival and tumor progression.
• Evaluation of potential adjunct therapies, such as mammalian target of rapamycin (mTOR) inhibitors and anti-vascular endothelial growth factor (VEGF) agents.

Main Results:

• Out of 22 reviewed cases, four patients maintained intact grafts without tumor progression after PD-1 inhibitor treatment.
• Successful outcomes were observed with varying immunosuppressive strategies, including maintenance of existing regimens, CNI-elimination with sirolimus, and combined therapies (anti-PD-1, anti-VEGF, chemotherapy).
• Preliminary findings suggest that mTOR inhibitors and anti-VEGF may play a role in modulating tumor-specific and allogeneic T-cell responses.

Conclusions:

• The use of PD-1 inhibitors in advanced cancer patients with kidney transplants presents a complex challenge balancing anti-tumor efficacy with the risk of allograft rejection.
• Specific immunosuppressive modifications, including CNI-elimination and the potential use of mTOR inhibitors and anti-VEGF therapy, may offer feasible approaches.
• Further research and larger studies are essential to establish optimal, safe, and effective treatment protocols for this vulnerable patient group.